Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 27124 | 195 | 22.2 | 64% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 2005 | 5003 | TELEPATHOLOGY//VIRTUAL MICROSCOPY//TELECYTOLOGY |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | SULFINOSINE | Author keyword | 4 | 75% | 2% | 3 |
| 2 | OPERAT UNIT MED STAT BIOMETRY | Address | 3 | 100% | 2% | 3 |
| 3 | EUROPEAN MOL GENET QUAL NETWORK | Address | 2 | 67% | 1% | 2 |
| 4 | BIOMED QUAL ASSURANCE UNIT | Address | 2 | 31% | 3% | 5 |
| 5 | GENET REFERENCE MANCHESTER | Address | 2 | 29% | 3% | 5 |
| 6 | UK NEQAS MOL GENET | Address | 1 | 38% | 2% | 3 |
| 7 | REFERENCE BIOANALYT | Address | 1 | 100% | 1% | 2 |
| 8 | ANALYTIC SENSITIVITY | Author keyword | 1 | 33% | 1% | 2 |
| 9 | PRACTICE EVALUAT | Address | 1 | 33% | 1% | 2 |
| 10 | ADV DIAGNOST INFORMAT TECHNOL | Address | 1 | 50% | 1% | 1 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | SULFINOSINE | 4 | 75% | 2% | 3 | Search SULFINOSINE | Search SULFINOSINE |
| 2 | ANALYTIC SENSITIVITY | 1 | 33% | 1% | 2 | Search ANALYTIC+SENSITIVITY | Search ANALYTIC+SENSITIVITY |
| 3 | DOXORUBICIN EFFLUX | 1 | 50% | 1% | 1 | Search DOXORUBICIN+EFFLUX | Search DOXORUBICIN+EFFLUX |
| 4 | EMQN | 1 | 50% | 1% | 1 | Search EMQN | Search EMQN |
| 5 | GRISCOFULVIN | 1 | 50% | 1% | 1 | Search GRISCOFULVIN | Search GRISCOFULVIN |
| 6 | RNA TESTING | 1 | 50% | 1% | 1 | Search RNA+TESTING | Search RNA+TESTING |
| 7 | TAGUCHIS ROBUST DESIGN METHOD | 1 | 50% | 1% | 1 | Search TAGUCHIS+ROBUST+DESIGN+METHOD | Search TAGUCHIS+ROBUST+DESIGN+METHOD |
| 8 | WORKSHOP PROGRAM | 1 | 50% | 1% | 1 | Search WORKSHOP+PROGRAM | Search WORKSHOP+PROGRAM |
| 9 | EXTERNAL PROFICIENCY TESTING | 1 | 29% | 1% | 2 | Search EXTERNAL+PROFICIENCY+TESTING | Search EXTERNAL+PROFICIENCY+TESTING |
| 10 | ANALYTIC SPECIFICITY | 0 | 33% | 1% | 1 | Search ANALYTIC+SPECIFICITY | Search ANALYTIC+SPECIFICITY |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | SULFINOSINE | 3 | 100% | 2% | 3 |
| 2 | GENOMIC REFERENCE MATERIALS | 2 | 67% | 1% | 2 |
| 3 | 5 YEAR SURVEY | 1 | 50% | 1% | 2 |
| 4 | CYCLERS | 1 | 50% | 1% | 2 |
| 5 | EUROPEAN PROGRAM | 1 | 100% | 1% | 2 |
| 6 | DIAGNOSTIC LABORATORIES | 1 | 25% | 2% | 3 |
| 7 | ASSESSMENT EQA | 1 | 50% | 1% | 1 |
| 8 | EUROGENTEST | 1 | 50% | 1% | 1 |
| 9 | HEMATOPOIETIC NEOPLASIAS | 1 | 50% | 1% | 1 |
| 10 | PARKIN MUTATIONS | 1 | 50% | 1% | 1 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
|---|---|---|---|---|
| Current Landscape and New Paradigms of Proficiency Testing and External Quality Assessment for Molecular Genetics | 2013 | 5 | 40 | 58% |
| Regulatory issues for genetic testing in clinical practice | 2008 | 0 | 2 | 100% |
| Molecular diagnostics: harmonization through reference materials, documentary standards and proficiency testing | 2011 | 10 | 34 | 15% |
| Quality assurance and quality control in the routine molecular diagnostic laboratory for infectious diseases | 2012 | 4 | 13 | 23% |
| Validation of Human Clinical Genetic Tests | 2014 | 0 | 10 | 40% |
| Quality control in mutation analysis: the European Molecular Genetics Quality Network (EMQN) | 2001 | 16 | 2 | 50% |
| Biomarkers for Early Cancer Detection - Methodological Aspects | 2010 | 0 | 16 | 25% |
| An overview of recommendations and translational milestones for genomic tests in cancer | 2015 | 0 | 14 | 21% |
| Standards in molecular diagnostics for the discovery and validation of clinically useful cancer biomarkers | 2013 | 0 | 9 | 22% |
| Next generation diagnostic molecular pathology: Critical appraisal of quality assurance in Europe | 2014 | 3 | 38 | 5% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | OPERAT UNIT MED STAT BIOMETRY | 3 | 100% | 1.5% | 3 |
| 2 | EUROPEAN MOL GENET QUAL NETWORK | 2 | 67% | 1.0% | 2 |
| 3 | BIOMED QUAL ASSURANCE UNIT | 2 | 31% | 2.6% | 5 |
| 4 | GENET REFERENCE MANCHESTER | 2 | 29% | 2.6% | 5 |
| 5 | UK NEQAS MOL GENET | 1 | 38% | 1.5% | 3 |
| 6 | REFERENCE BIOANALYT | 1 | 100% | 1.0% | 2 |
| 7 | PRACTICE EVALUAT | 1 | 33% | 1.0% | 2 |
| 8 | ADV DIAGNOST INFORMAT TECHNOL | 1 | 50% | 0.5% | 1 |
| 9 | BIOMED SCI CURTIN HLTH INNOVAT | 1 | 50% | 0.5% | 1 |
| 10 | CAMBRIDGE HUNTINGDON HLTH AUTHOR | 1 | 50% | 0.5% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000092319 | DIRECT TO CONSUMER//PUBLIC HEALTH GENOMICS//DIRECT TO CONSUMER GENETIC TESTING |
| 2 | 0.0000091049 | EUROPEAN REGISTER//EC4//CLINICAL CHEMISTRY AND LABORATORY MEDICINE |
| 3 | 0.0000090169 | PHARMACOGENOMICS//PERSONALIZED MEDICINE//PROGRAM PERSONALIZED MED TARGETED THER EUT |
| 4 | 0.0000082309 | EIDGENOSS FOR ANSTALT AGARWIRT AFT LANDTEC//HIGH LEVEL OF PROTECTION//WASTE EXPORTS |
| 5 | 0.0000076570 | QF PCR//UNCULTURED AMNIOCYTES//RAPID ANEUPLOIDY DETECTION |
| 6 | 0.0000074465 | CYSTIC FIBROSIS//CFTR GENE//CBAVD |
| 7 | 0.0000066614 | HCV CORE ANTIGEN//HCV CORE ANTIGEN ASSAY//HCV RNA STABILITY |
| 8 | 0.0000062764 | MERIEUX//BLOOD TRANSCRIPTOME//DUTCH NUTRIGENOM CONSORTIUM |
| 9 | 0.0000061081 | SYST STAND//WHEATLEY STRESS PROFILE//BOARD REGISTRY |
| 10 | 0.0000060454 | HIGH RESOLUTION MELTING//HIGH RESOLUTION MELTING ANALYSIS HRM//HRMA |